SCHEMBL1122722

SCHEMBL1122722

COC(=O)c1cccc(OCc2ccc(OCc3ccccc3)cc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.68
NR4A2 P43354 3/20 0.67
MRGPRX4 Q96LA9 4/20 0.66
SMPD1 P17405 3/20 0.64
PTPN1 P18031 1/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
SRD5A2 P31213 1/20 0.59
LMNA P02545 1/20 0.58
HPGD P15428 1/20 0.58
FFAR1 O14842 1/20 0.58
CYSLTR1 Q9Y271 1/20 0.57
TP53 P04637 1/20 0.57
PKM P14618 1/20 0.57
NFKB1 P19838 1/20 0.57
RAB9A P51151 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30412034 0.96 MAOB (0.73) MAOBNR4A2MRGPRX4SMPD1PTPN1
SCHEMBL976424 0.96 MAOB (0.73) MAOBNR4A2MRGPRX4SMPD1PTPN1
SCHEMBL1122805 0.93 MRGPRX4 (0.71) MAOBNR4A2MRGPRX4SMPD1PTPN1
SCHEMBL2254423 0.90 SMPD1 (0.76) MAOBNR4A2MRGPRX4SMPD1SMN1; SMN2
SCHEMBL28757742 0.89 MRGPRX4 (0.65) MAOBMRGPRX4MEN1KMT2ASMN1; SMN2
SCHEMBL1122731 0.89 SMN1; SMN2 (0.64) MAOBNR4A2MRGPRX4SMPD1PTPN1
SCHEMBL10411878 0.88 MRGPRX4 (0.77) MAOBNR4A2MRGPRX4SMPD1CYSLTR1
SCHEMBL1171850 0.88 MRGPRX4 (0.65) MAOBNR4A2MRGPRX4SMPD1PTPN1
SCHEMBL28768851 0.88 MAOB (0.58) MAOBNR4A2MRGPRX4SMPD1PTPN1
SCHEMBL25196508 0.86 SMPD1 (0.73) MAOBNR4A2MRGPRX4SMPD1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644321-B1 NEW BENZAMIDES AS PPATY MODULATORS S A L V A T LAB SA (ES) 2011-02-09 EP disclosed
US-20060160894-A1 Benzamides as ppar modulators LABORATORIOS S.A.L.V.A.T.,S.A. (ES) 2006-07-20 US disclosed
EP-1644321-A2 NEW BENZAMIDES AS PPATY MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-04-12 EP disclosed
WO-2004110983-A2 NEW BENZAMIDES AS PPARϒ MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160894-A1 Benzamides as ppar modulators PPARD, PPARA, PPARG MAOB 1188/4885NR4A2 66/4885MRGPRX4 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.